277 assets in Small Cell Lung Carcinoma

Therapeutic assets addressing Small Cell Lung Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
ibi363 Small Cell Lung Carcinoma	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	P2	CCC (53)
JS201 Small Cell Lung Carcinoma	Hunan Province Tumor Hospital	P2	CCC (53)
Lamivudine Small Cell Lung Carcinoma	Roswell Park Cancer Institute	P2	CCC (53)
Ligufalimab Small Cell Lung Carcinoma	Akeso	P2	CCC (53)
Lomustine Small Cell Lung Carcinoma	Yayi He	P2	CCC (53)
Mirabegron Small Cell Lung Carcinoma	Zhejiang Provincial People's Hospital	P2	CCC (53)
Monalizumab Small Cell Lung Carcinoma	SWOG Cancer Research Network	P2	CCC (53)
Nanocrystalline Megestrol Acetate Suspension Small Cell Lung Carcinoma	Guangzhou Institute of Respiratory Disease	P2	CCC (53)
Pamiparib Small Cell Lung Carcinoma	Fudan University	P2	CCC (53)
Pimurutamab Small Cell Lung Carcinoma	Shanghai Henlius Biotech	P2	CCC (53)
Polo-Like Kinase 1 Inhibitor Nms-1286937 Small Cell Lung Carcinoma	University of Maryland, Baltimore	P2	CCC (53)
Tafolecimab Small Cell Lung Carcinoma	Second Affiliated Hospital, School of Medicine, Zhejiang University	P2	CCC (53)
Teniposide Small Cell Lung Carcinoma	Shanghai Pulmonary Hospital, Shanghai, China	P2	CCC (53)
Utidelone Small Cell Lung Carcinoma	Henan Cancer Hospital	P2	CCC (53)
Belinostat Small Cell Lung Carcinoma	National Cancer Institute (NCI)	P2	CCC (52)
Oxodotreotide Small Cell Lung Carcinoma	Peking University Cancer Hospital & Institute	P1/2	CCC (52)
Tinengotinib Small Cell Lung Carcinoma	TransThera Sciences (Nanjing), Inc.	P1/2	CCC (52)
Ceralasertib Small Cell Lung Carcinoma	SWOG Cancer Research Network	P2	CCC (51)
Immunoglobulin Half-Ig G1-Kappa/Scfv-H-Ch2-Ch3, Anti-(Homo Sapiens Ctla4 (Cytotoxic T-Lymphocyte-Associated Protein 4, Cd152)) And Anti-(Homo Sapienspdcd1 (Programmed Cell Death 1, Pd-1, Pd1, Cd279)), Monoclonal Antibody, Bispecific Small Cell Lung Carcinoma	M.D. Anderson Cancer Center	P2	CCC (51)
Pegargiminase Small Cell Lung Carcinoma	Washington University School of Medicine	P2	CCC (51)
Radiosensitizer Rrx-001 Small Cell Lung Carcinoma	EpicentRx, Inc.	P3	CCC (51)
Simvastatin Small Cell Lung Carcinoma	Shanghai Pulmonary Hospital, Shanghai, China	P2	CCC (51)
Sitravatinib Small Cell Lung Carcinoma	Zhejiang Cancer Hospital	P2	CCC (49)
1-(4,4-BIS(P-FLUOROPHENYL)BUTYL)-4-(4-CHLORO-.ALPHA.,.ALPHA.,.ALPHA.-TRIFLUORO-M-TOLYL)-4-PIPERIDINOL Small Cell Lung Carcinoma	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	P1/2	CCC (48)
177lu-betabart Small Cell Lung Carcinoma	Radiopharm Theranostics, Ltd	P1/2	CCC (48)
Avelumab Small Cell Lung Carcinoma	Ariceum Therapeutics GmbH	P2	CCC (48)
b1962 Small Cell Lung Carcinoma	Tasly Biopharmaceuticals Co., Ltd.	P2	CCC (48)
Bms-986525 Small Cell Lung Carcinoma	Bristol-Myers Squibb	P1/2	CCC (48)
Camibirstat Small Cell Lung Carcinoma	Dana-Farber Cancer Institute	P2	CCC (48)
Camizestrant Small Cell Lung Carcinoma	AstraZeneca	P1/2	CCC (48)
Datopotamab Deruxtecan Small Cell Lung Carcinoma	AstraZeneca	P1/2	CCC (48)
hlx43 Small Cell Lung Carcinoma	Shanghai Henlius Biotech	P2	CCC (48)
ibb0979 Small Cell Lung Carcinoma	SUNHO（China）BioPharmaceutical CO., Ltd.	P2	CCC (48)
Jab-2485 Small Cell Lung Carcinoma	Jacobio Pharmaceuticals Co., Ltd.	P1/2	CCC (48)
Kl-A167 Small Cell Lung Carcinoma	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	P2	CCC (48)
Letrozole Small Cell Lung Carcinoma	Pfizer	P2	CCC (48)
Limertinib Small Cell Lung Carcinoma	Hunan Province Tumor Hospital	P2	CCC (48)
Pd-L1 T-Hank Small Cell Lung Carcinoma	ImmunityBio, Inc.	P2	CCC (48)
PF-0704091 Small Cell Lung Carcinoma	Pfizer	P2	CCC (48)
Si-B003 Small Cell Lung Carcinoma	Sichuan Baili Pharmaceutical Co., Ltd.	P2	CCC (48)
Simridarlimab Small Cell Lung Carcinoma	Hunan Province Tumor Hospital	P2	CCC (48)
skb500 Small Cell Lung Carcinoma	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	P2	CCC (48)
Stenoparib Small Cell Lung Carcinoma	VA Office of Research and Development	P1/2	CCC (48)
T-Dxd Small Cell Lung Carcinoma	AstraZeneca	P1/2	CCC (48)
Tegtociclib Small Cell Lung Carcinoma	Pfizer	P2	CCC (48)
Transcon Il-2 Β/Γ Small Cell Lung Carcinoma	Ascendis Pharma Oncology Division A/S	P1/2	CCC (48)
Transcon Tlr7/8 Agonist Small Cell Lung Carcinoma	Ascendis Pharma Oncology Division A/S	P1/2	CCC (48)
Trastuzumab Emtansine Small Cell Lung Carcinoma	Ascendis Pharma Oncology Division A/S	P1/2	CCC (48)
Vunakizumab Small Cell Lung Carcinoma	Fujian Cancer Hospital	P2	CCC (48)
Benzoic Acid, 4-((4-Amino-3-(4-Cyclohexyl-1-Piperazinyl)-9,10-Dihydro-9,10-Dioxo-1-Anthracenyl)Amino)- Small Cell Lung Carcinoma	VM Oncology, LLC	P1/2	CC (47)

Showing 101 to 150 of 277 assets

PreviousPage 3 of 6Next